{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:10:51Z","timestamp":1790935851138,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00975-3","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T03:58:37Z","timestamp":1756871917000},"page":"1003-1016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2044","authenticated-orcid":false,"given":"Alan D.","family":"Irvine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F. Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Calimlim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza M.","family":"Raymundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"issue":"10247","key":"975_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"12","key":"975_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343. https:\/\/doi.org\/10.1056\/NEJMra2023911.","journal-title":"N Engl J Med"},{"issue":"1","key":"975_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21\u201340. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"975_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","volume":"25","author":"RW Kim","year":"2024","unstructured":"Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol. 2024;25(2):179\u201393. https:\/\/doi.org\/10.1007\/s40257-023-00837-w.","journal-title":"Am J Clin Dermatol"},{"key":"975_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. https:\/\/doi.org\/10.1186\/s41927-018-0031-x.","journal-title":"BMC Rheumatol."},{"key":"975_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/annrheumdis-2014-eular.3823","volume":"73","author":"J Voss","year":"2014","unstructured":"Voss J, Graff C, Schwartz A, Hyland D, Argiriadi M, Camp HS, et al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Ann Rheum Dis. 2014;73:222. https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.3823.","journal-title":"Ann Rheum Dis"},{"key":"975_CR7","unstructured":"RINVOQ (upadacitinib). Prescribing information. AbbVie Inc., 2025. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 23 Apr 2025."},{"issue":"10290","key":"975_CR8","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/s0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"10290","key":"975_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/s0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(21)00589-4.","journal-title":"Lancet"},{"issue":"4","key":"975_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404\u201313. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0029.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"975_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","volume":"149","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149(3):977-87.e14. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.036.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"975_CR12","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348. https:\/\/doi.org\/10.1111\/jdv.20229.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"975_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839\u201346. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.104.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"975_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaci.2016.01.015","volume":"138","author":"YMF Andersen","year":"2016","unstructured":"Andersen YMF, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):310-2.e3. https:\/\/doi.org\/10.1016\/j.jaci.2016.01.015.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"975_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1001\/jamadermatol.2023.1300","volume":"159","author":"TL Chen","year":"2023","unstructured":"Chen TL, Huang WT, Loh CH, Huang HK, Chi CC. Risk of venous thromboembolism among adults with atopic dermatitis. JAMA Dermatol. 2023;159(7):720\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2023.1300.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"975_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100338","volume":"3","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Wollenberg A, Bieber T, Lemeshow AR, Vyas S. Incidence of cardiovascular events in a population-based Danish cohort with atopic dermatitis. J Allergy Clin Immunol Glob. 2024;3(4): 100338. https:\/\/doi.org\/10.1016\/j.jacig.2024.100338.","journal-title":"J Allergy Clin Immunol Glob."},{"issue":"10","key":"975_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","volume":"156","author":"KE Mansfield","year":"2020","unstructured":"Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086\u201397. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1948.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"975_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s13555-021-00538-4","volume":"11","author":"KJ Meyers","year":"2021","unstructured":"Meyers KJ, Silverberg JI, Rueda MJ, Goodloe R, Pierce EJ, Deberdt W, et al. Risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a US administrative claims database. Dermatol Ther (Heidelb). 2021;11(3):1041\u201352. https:\/\/doi.org\/10.1007\/s13555-021-00538-4.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"975_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","volume":"157","author":"MC Schneeweiss","year":"2021","unstructured":"Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, et al. Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases. JAMA Dermatol. 2021;157(7):805\u201316. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1570.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"975_CR20","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"975_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/jdv.15919","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, St\u00e4nder S, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142\u201352. https:\/\/doi.org\/10.1111\/jdv.15919.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"975_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","volume":"25","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, et al. Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase III randomized clinical trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol. 2024;25(3):485\u201396. https:\/\/doi.org\/10.1007\/s40257-024-00853-4.","journal-title":"Am J Clin Dermatol"},{"key":"975_CR23","doi-asserted-by":"publisher","first-page":"ii72","DOI":"10.1093\/bjd\/ljae266.070","volume":"191","author":"VH Prajapati","year":"2024","unstructured":"Prajapati VH, Bunick C, Eyerich K, Stein Gold LF, Galimberti F, Calimlim B, et al. Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. Br J Dermatol. 2024;191:ii72\u20133. https:\/\/doi.org\/10.1093\/bjd\/ljae266.070.","journal-title":"Br J Dermatol"},{"key":"975_CR24","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/jdv.18995","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, de Bruin-Weller MS, Deleuran M, Calimlim BM, Chen N, Hu X, et al. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: integrated analysis of three upadacitinib phase 3 trials. J Eur Acad Dermatol Venereol. 2023;37:1634\u201341. https:\/\/doi.org\/10.1111\/jdv.18995.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"975_CR25","doi-asserted-by":"publisher","first-page":"2428729","DOI":"10.1080\/09546634.2024.2428729","volume":"35","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Calimlim BM, Grada A, Bunick CG, Gooderham MJ, Shi VY, et al. Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry. J Dermatolog Treat. 2024;35(1):2428729. https:\/\/doi.org\/10.1080\/09546634.2024.2428729.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"975_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004007","volume":"10","author":"R Fleischmann","year":"2024","unstructured":"Fleischmann R, Swierkot J, Penn SK, Durez P, Bessette L, Bu X, et al. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open. 2024;10(2): e004007. https:\/\/doi.org\/10.1136\/rmdopen-2023-004007.","journal-title":"RMD Open"},{"key":"975_CR27","doi-asserted-by":"publisher","first-page":"ii35","DOI":"10.1093\/bjd\/ljad498.037","volume":"190","author":"C Bunick","year":"2024","unstructured":"Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, et al. Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. Br J Dermatol. 2024;190:ii35\u20136. https:\/\/doi.org\/10.1093\/bjd\/ljad498.037.","journal-title":"Br J Dermatol"},{"issue":"1","key":"975_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1): e002735. https:\/\/doi.org\/10.1136\/rmdopen-2022-002735.","journal-title":"RMD Open"},{"issue":"12","key":"975_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","volume":"55","author":"MF Mohamed","year":"2016","unstructured":"Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547\u201358. https:\/\/doi.org\/10.1007\/s40262-016-0419-y.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"975_CR30","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/jdv.19254","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, et al. Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2047\u201355. https:\/\/doi.org\/10.1111\/jdv.19254.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"975_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.20873","volume":"186","author":"K Kabashima","year":"2022","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2022;186(4):642\u201351. https:\/\/doi.org\/10.1111\/bjd.20873.","journal-title":"Br J Dermatol"},{"issue":"1","key":"975_CR32","doi-asserted-by":"publisher","first-page":"2190430","DOI":"10.1080\/09546634.2023.2190430","volume":"34","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Werfel T, Barbarot S, Hunter HJA, Pierce E, Sun L, et al. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. J Dermatol Treat. 2023;34(1):2190430. https:\/\/doi.org\/10.1080\/09546634.2023.2190430.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"975_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.019.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"975_CR34","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1536.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"975_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"key":"975_CR36","doi-asserted-by":"publisher","first-page":"ii112","DOI":"10.1093\/bjd\/ljae404","volume":"191","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick C, Hong HC, Mendes-Bastos P, Stein Gold LF, Costanzo A, et al. Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b\/4 study (Level Up). Br J Dermatol. 2024;191:ii112\u20133. https:\/\/doi.org\/10.1093\/bjd\/ljae404.","journal-title":"Br J Dermatol"},{"issue":"10","key":"975_CR37","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","volume":"13","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Hong HC, Calimlim BM, Lee WJ, Teixeira HD, Collins EB, et al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol Ther (Heidelb). 2023;13(10):2247\u201364. https:\/\/doi.org\/10.1007\/s13555-023-01000-3.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"975_CR38","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL, Wong MM, Rayner DG, Guyatt GH, D\u00edaz Martinez JP, Ceccacci R, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470\u201392. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"975_CR39","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160(9):936\u201344. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2192.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"975_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023.","journal-title":"J Allergy Clin Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00975-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:45:46Z","timestamp":1763048746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00975-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00975-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"21 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AbbVie Inc. (North Chicago, IL, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan, and execution of a Data Sharing Agreement. Data requests can be submitted at any time after approval in the United States and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      then select \u201cHome.\u201d","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Concept and design: Alan D. Irvine, Emma Guttman-Yassky, Eric L. Simpson, Kim A. Papp, Thomas Bieber, Brian M. Calimlim, Henrique D. Teixeira, and Jonathan I. Silverberg. Data acquisition: Alan D. Irvine, Vimal H. Prajapati, Emma Guttman-Yassky, Eric L. Simpson, Kim A. Papp, Andrew Blauvelt, Chia-Yu Chu, H. Chih-ho Hong, Linda F. Stein Gold, Marjolein de Bruin-Weller, Thomas Bieber, Kenji Kabashima, David Rosmarin, and Jonathan I. Silverberg. Statistical analysis: Brian M. Calimlim, Yang Yang, Xiaoqiang Wu, and Henrique D. Teixeira. Data interpretation: Alan D. Irvine, Vimal H. Prajapati, Emma Guttman-Yassky, Eric L. Simpson, Kim A. Papp, Andrew Blauvelt, H. Chih-ho Hong, Marjolein de Bruin-Weller, Thomas Bieber, Kenji Kabashima, Cristina Sancho, Brian M. Calimlim, Ayman Grada, Yang Yang, Xiaoqiang Wu, Gweneth Levy, Eliza M. Raymundo, Henrique D. Teixeira, and Jonathan I. Silverberg. All authors critically reviewed the manuscript and provided their final approval for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"ADI\n                      has served as a speaker and\/or consultant for AbbVie, Alexion, Almirall, Apollo, Arena, Dermavant, Galderma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sitryx, and UCB.\n                      VHP\n                      has served as an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, LEO Pharma, Lilly, Medexus, Novartis, Organon, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB. He has served as an investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics. He has received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme.\n                      EG-Y\n                      is an employee of Mount Sinai and has received research grants (paid to the institution) from AbbVie, Aclaris, Amgen, AnaptysBio, Apollo, Arcutis, Bristol Meyers Squibb, Concerto Biosciences, Galderma, GSK, Incyte, Inmagene, LEO, Lilly, Opsidio, Pfizer, Q32 Bio, Regeneron, Sanofi, and Xencor. She is also a consultant for AbbVie, Aclaris, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Apollo, Arcutis, Artax Biopharma, Astria, Boehringer Ingelheim, Bristol Meyers Squibb, Celldex, Centrexion, Connect Biopharm, Coty, DBV, Dualitas, Enveda Biosciences, Escient, Galderma, Gate Bio, GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper, Kymera, Kyowa Kirin, LEO Pharma, Lilly, Matchpoint, Merck, Nektar, NUMAB, OTSUKA, Pfizer, Pharmaxis, Proteologix, RAPT, RayThera, Regeneron, Ribon, Sanofi, SATO, Schr\u00f6dinger, Sitryx, Sun Pharma, Takeda, Teva, TRex Bio, UCB, and VRG.\n                      ELS\n                      has received personal fees from AbbVie, Amgen, Arcutis, Astria, Castle, CorEvitas, Dermira, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, LEO Pharma, Lilly, Numab, Pfizer, Recludix, Regeneron, Roche, Sanofi-Genzyme, and Sitryx, and has received grants from and\/or served as a principal investigator for AbbVie, Acrotech, Amgen, Arcutis, Aslan, Castle, Dermavant, CorEvitas, Dermira, Incyte, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, Target, and VeriSkin.\n                      KAP\n                      has received honoraria and\/or grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab.\n                      AB\n                      has served as a speaker (received honoraria) for Lilly and UCB and has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, and Company, Galderma, GlaxoSmithKline, Incyte, IQVIA, Janssen, LEO Pharma, Lilly Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, UCB, and Union. He has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB, and owns stock in Lipidio and Oruka.\n                      C-YC\n                      has served as an investigator, consultant, speaker, and\/or advisory board member for AbbVie, Amgen, Dermira, Janssen, Lilly, Mylan, Novartis, Oneness Biotech, Pfizer, Regeneron, Roche, Sanofi, and Viatris.\n                      HCH\n                      has served as a consultant, advisory board member, and\/or speaker for AbbVie, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly, MedImmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Sun Pharma, and UCB. He has received research grants for investigator services from AbbVie, Akros, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Evelo, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly, Medimmune, Novartis, Pfizer, Regeneron\/Sanofi, Roche, and UCB.\n                      LFSG\n                      has served as an investigator, speaker, and\/or advisor for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, ASLAN, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Coherus, Dermira, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, and UCB.\n                      MdeB-W\n                      has served as a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Amgen, Aslan, Galderma, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi, and Takeda.\n                      TB\n                      has served as a speaker, consultant, and\/or investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, Anergis, AOBiom, Apogee, Arena, Aristea, Artax, Asana Biosciences, ASLAN, Astria, Attovia, BambusTx, Bayer Health, Biofilm control, BioVerSys, Boehringer Ingelheim, Bristol Myers Squibb, BYOME Labs, Connect Pharma, Daiichi Sankyo, Dermavant, DICE, Domain, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GlaxoSmithKline, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO Pharma, LG Chem, Lilly, L\u00b4Or\u00e9al, MSD, Medac, Micreos, Nektar, Nextech, Novartis, Numab, OM-Pharma, Ornavi, Overtone, Pfizer, Pierre Fabre, Q32bio, RAPT, Samsung Bioepis, Sanofi\/Regeneron, TIRmed, UCB, Union, UPStream Bio, and Yuhan. He is founder and chairman of the board of the nonprofit biotech Davos Biosciences AG within the international K\u00fchne-Foundation and founder of the consulting firm Bieber Dermatology Consulting.\n                      KK\n                      has received consulting fees, honoraria, grant support, and\/or lecturing fees from AbbVie, Amgen, Chugai Pharmaceutical, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Japan Tobacco, LEO Pharma, Lilly Japan, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Pola Pharma, Procter & Gamble, Sanofi, Taiho, Tanabe Mitsubishi, and Torii Pharmaceutical.\n                      DR\n                      has consulted, spoken for, or conducted trials for AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Dualitas, EMD Serono, Galderma, Incyte, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharma, UCB, VielaBio, and Zura Bio\n                      .\n                      CS\n                      ,\n                      BMC\n                      ,\n                      AG\n                      ,\n                      YY\n                      ,\n                      XW\n                      ,\n                      GL\n                      , and\n                      HDT\n                      are full-time employees of AbbVie, and may hold AbbVie stock, stock options, and\/or patents.\n                      EMR\n                      is a former employee of AbbVie, and may hold AbbVie stock, stock options, and\/or patents.\n                      JIS\n                      has received consulting fees from and\/or served as an investigator for AbbVie, Anacor, Celgene, GlaxoSmithKline, Lilly, MedImmune, P&G, Pfizer, Regeneron, and Roche.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the protocol, International Council for Harmonisation guidelines, and applicable regulations, guidelines, and ethical principles originating from the Declaration of Helsinki. The study protocol was reviewed and approved by a central institutional review board (Advarra, Inc.; registered with the Office for Human Research Protections and the United States Food and Drug Administration under IRB#00000971). The Advarra approval numbers for each study are as follows: Measure Up 1, Pro00034417; Measure Up 2, Pro00034418; AD UP, Pro00034416.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before screening or undergoing study-specific procedures.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}